EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interaction Between Inflammaging and Common Cardiovascular Diseases: Current Knowledge and Treatment

Anna Tylutka, Łukasz Walas, Paweł Muszyński, Katarzyna Koleśnik, Jarosław Hiczkiewicz, Agnieszka Zembron‐Lacny

Comprehensive Physiology · 2026-12 · 16 (6)

DOI: 10.1002/cph4.70288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Comprehensive Physiology, online erschienen am 18.11.2026. Verfasst von Anna Tylutka und 5 weiteren Autor:innen. Die Arbeit nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammation plays a key role in the pathogenesis of major cardiovascular diseases such as hypertension, atherosclerosis, and heart failure. Chronic immune activation leads to endothelial dysfunction, contributing to increased oxidative stress, and abnormal neurohormonal responses. In patients with hypertension, vascular constriction, increased stiffness, and vascular wall remodeling occur, and activation of the renin–angiotensin–aldosterone system (RAAS) intensifies the inflammatory response through the action of angiotensin II, which stimulates the production of reactive oxygen species and inflammatory mediators. In patients with atherosclerosis, oxidized LDL activates endothelial cells and attracts monocytes, which migrate to the vessel wall and differentiate into macrophages. As the disease progresses, further activation of the immune system occurs, along with the secretion of proinflammatory cytokines (including IL‐1β, IL‐6, and TNF‐α), and proliferation of smooth muscle cells, leading to the formation of atherosclerotic plaque. In the case of heart failure, the role of the NLRP3 inflammasome is crucial, as it activates IL‐1β and intensifies the inflammatory response in the myocardium, contributing to the progression of heart failure. Progress in understanding immunological mechanisms has led to the development of modern therapeutic strategies aimed at addressing the inflammatory process. In addition to classic pleiotropic drugs such as statins and ACE inhibitors, targeted therapies are gaining increasing importance, including interleukin‐1 inhibitors (e.g., canakinumab), colchicine, and IL‐6 inhibitors, which have been shown to reduce cardiovascular risk regardless of lipid levels. Integration of modern anti‐inflammatory therapies with standard treatment opens up new possibilities for improving patient prognosis and personalizing therapy.

Zitieren

APA

Tylutka, A., Walas, Ł., Muszyński, P., Koleśnik, K., Hiczkiewicz, J., & Zembron‐Lacny, A. (2026). Interaction Between Inflammaging and Common Cardiovascular Diseases: Current Knowledge and Treatment. Comprehensive Physiology, 16(6). https://doi.org/10.1002/cph4.70288

Vancouver

Tylutka A, Walas Ł, Muszyński P, Koleśnik K, Hiczkiewicz J, Zembron‐Lacny A. Interaction Between Inflammaging and Common Cardiovascular Diseases: Current Knowledge and Treatment. Comprehensive Physiology. 2026;16(6). doi:10.1002/cph4.70288

BibTeX
@article{Tylutka2026,
  author = {Tylutka, Anna and Walas, Łukasz and Muszyński, Paweł and Koleśnik, Katarzyna and Hiczkiewicz, Jarosław and Zembron‐Lacny, Agnieszka},
  title = {Interaction Between Inflammaging and Common Cardiovascular Diseases: Current Knowledge and Treatment},
  journal = {Comprehensive Physiology},
  year = {2026},
  volume = {16},
  number = {6},
  doi = {10.1002/cph4.70288}
}
Kostenlos starten →